|Table of Contents|

Correlation between depth of tumour response and survival in extensive stage SCLC

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2019 04
Page:
591-594
Research Field:
Publishing date:

Info

Title:
Correlation between depth of tumour response and survival in extensive stage SCLC
Author(s):
Xu Long; Zhang Guanzhong; Xie Xiaodong; Zheng Zhendong
Department of Oncology,the General Hospital of Northern Theater Command,Liaoning Shenyang 110016，China.
Keywords:
depth of response; survival; SCLC; retrospective study
PACS:
R734.2
DOI:
10.3969/j.issn.1672-4992.2019.04.012
Abstract:
Objective:To assess the relationship between depth of response and survival in extensive stage SCLC after first-line therapy.Methods:50 patients with extensive stage SCLC were included in the retrospective analysis.Spearman rank correlation was used to evaluate the relationship between depth of response and PFS and OS.Log-rank test was used for univariate analysis,and COX proportional regression model was used for multivariate analysis.Results:Spearman rank correlation analysis and linear regression analysis showed that depth of response was moderately correlated with PFS and OS.According to the results of multivariate analysis,weight loss＜5%（P＜0.000 1）,depth of response（P＜0.001） were independent prognostic factors for PFS of extensive stage SCLC,and weight loss＜5%（P＜0.000 1）,ECOG PS 0~1（P=0.001 2）,depth of response（P＜0.001）,chemotherapy cycles≥4（P=0.000 2） and second line chemotherapy（P=0.006 7） were independent prognostic factors for OS of extensive stage SCLC.Conclusion:Depth of response was a prognostic factor for PFS and OS in patients with extensive stage SCLC first-line therapy patients.

References:

［1］Pesek M,Muzik J.Small-cell lung cancer:Epidemiology,diagnostics and therapy［J］.Vnitr Lek,2018,63(11):876-883.
［2］Koinis F,Kotsakis A,Georgoulias V.Small cell lung cancer (SCLC):no treatment advances in recent years［J］.Transl Lung Cancer Res,2016,5(1):39-50.
［3］Alvarado Luna G,Morales Espinosa D.Treatment for small cell lung cancer,where are we now-a review［J］.Transl Lung Cancer Res,2016,5(1):26-38.
［4］Hutchinson L.Tumour response,correlates of survival and clinical benefit［J］.Nat Rev Clin Oncol,2015,12(8):433.
［5］Mansmann U,Sartorius U,Laubender R,et al.Quantitative analysis of the impact of deepness of response on post-progression survival time following first-line treatment in patients with mCRC［J］.Annals of Oncology,2013,24(suppl 4):iv14-iv15.
［6］Taieb J,Rivera F,Siena S,et al.Exploratory analyses assessing the impact of early tumour shrinkage and depth of response on survival outcomes in patients with RAS wild-type metastatic colorectal cancer receiving treatment in three randomised panitumumab trials［J］.J Cancer Res Clin Oncol,2018,144(2):321-335.
［7］Saad ED,Buyse M.Exploratory analysis of the association of depth of response and survival in patients with metastatic non-small-cell lung cancer treated with a targeted therapy or immunotherapy［J］.Ann Oncol,2017,28(11):2629-2630.
［8］Osumi H,Takahari D,Shinozaki E,et al.Associations between early tumor shrinkage and depth of response and clinical outcomes in patients treated with 1st-line chemotherapy for advanced gastric cancer［J］.Gastric Cancer,2018,21(2):267-275.
［9］McCoach CE,Blumenthal GM,Zhang L,et al.Exploratory analysis of the association of depth of response and survival in patients with metastatic non-small-cell lung cancer treated with a targeted therapy or immunotherapy［J］.Ann Oncol,2017,28(11):2707-2714.
［10］Chen W,Zheng R,Baade PD,et al.Cancer statistics in China,2015［J］.CA Cancer J Clin,2016,66(2):115-132.
［11］Siegel RL,Miller KD,Jemal A.Cancer statistics,2016［J］.CA Cancer J Clin,2016,66(1):7-30.
［12］Cremolini C,Loupakis F,Antoniotti C,et al.Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab:Results from phase III TRIBE trial by the Gruppo Oncologico del Nord Ovest［J］.Ann Oncol,2015,26(6):1188-1194.
［13］Weber S,Wolkewitz M,Schumacher M.Analyzing the impact of depth of response on survival in patients with metastatic non-small-cell lung cancer［J］.Ann Oncol,2018,29(1):282-283.
［14］Lee CK,Kim SS,Park S,et al.Depth of response is a significant predictor for long-term outcome in advanced gastric cancer patients treated with trastuzumab［J］.Oncotarget,2017,8(19):31169-31179.
［15］Imai H,Mori K,Wakuda K,et al.Progression-free survival,post-progression survival,and tumor response as surrogate markers for overall survival in patients with extensive small cell lung cancer［J］.Ann Thorac Med,2015,10(1):61-66.
［16］Hernandez Quiles C,Bernabeu Wittel M,Perez Belmonte LM,et al.Concordance of Barthel Index,ECOG-PS,and Palliative Performance Scale in the assessment of functional status in patients with advanced medical diseases［J］.BMJ Support Palliat Care,2017,7(3):300-307.
［17］Therasse P.Measuring the clinical response.What does it mean［J］?Eur J Cancer,2002,38(14):1817-1823.
［18］Piessevaux H,Buyse M,Schlichting M,et al.Use of early tumor shrinkage to predict long-term outcome in metastatic colorectal cancer treated with cetuximab［J］.J Clin Oncol,2013,31(30):3764-3775.

Memo

Memo:
-
Last Update: 1900-01-01